The tonic-clonic seizures treatment market was valued at USD 4.79 Billion in 2025 and is expected to grow at a CAGR of 6.50%, reaching USD 8.99 Billion by 2035. The market growth is driven by rising prevalence of epilepsy and development of novel anti-seizure therapies.
Base Year
Historical Period
Forecast Period
The increasing prevalence of epilepsy and related seizure disorders is a major driver of the market.
Growth in research activities and clinical trials aimed at finding new treatments for tonic-clonic seizures are poised to elevate the market value in the forecast period.
The increased availability of generic drugs, rising demand for combination therapies, and growing awareness about tonic-clonic seizures are some of the factors impacting market dynamics.
Compound Annual Growth Rate
6.5%
Value in USD Billion
2026-2035
*this image is indicative*
Tonic-clonic seizures, also called grand mal seizures, refer to a type of generalized seizure that affects the entire brain of the individual. Tonic-clonic seizures combine the characteristics of tonic and clonic seizures, as the name implies. Tonic refers to stiffening, while clonic refers to rhythmical jerking. For the diagnosis of the tonic-clonic, the medical history is reviewed prior to the tests such as neurological exams, blood tests, electroencephalogram (EEG), computerized tomography (CT) scan, and others. The continued cooperation of many organizations and governments in the fight against the stigma associated with epilepsy and seizures has resulted in increased awareness and a corresponding increase in demand for treatment.
Increased clinical trial activity has resulted in a stronger product pipeline, which is contributing to market growth. Technological advancements and increased investments in R&D activities have paved the way for a variety of novel treatment options. Furthermore, increased healthcare budget and spending and improved healthcare infrastructure are expected to support market growth over the forecast period.
Increasing Availability of Generic Medications for Tonic-Clonic Seizures to Support Market Growth
The market is witnessing an increased availability of generic drugs, which are generally less expensive than the branded versions. For instance, in July 2024 , the global pharmaceutical company, Lupin, announced that it had received approval for its Abbreviated New Drug Application (ANDA) for Topiramate Extended-Release Capsules from the United States Food and Drug Administration (U.S. FDA). The company will manufacture and market Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, and 200 mg, which is a generic version of Trokendi XR Extended-Release Capsules, 25 mg, 50 mg, 100 mg, and 200 mg, developed by Supernus Pharmaceuticals. This generic medication is indicated for partial-onset or primary generalized tonic-clonic seizures in patients (aged 6 years of age or above) and will be produced at Lupin’s Pithampur facility in India.
Thus, the increasing introduction of generic options is expected to improve treatment accessibility and also drive market growth.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The EMR’s report titled “Tonic-Clonic Seizures Treatment Market Report and Forecast 2026-2035" offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Market Breakup by Drug Generation
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Region
Drug Class Segment Represents a Major Market Share
The market is segmented by drug class into barbiturates, hydantoin, phenyltriazine, iminostilbenes, and others. The market value of this segment is influenced by the introduction of new drugs and changes in treatment guidelines. The hydantoin segment is experiencing significant demand in the market and is commonly prescribed as a first-line treatment for tonic-clonic seizures. The efficacy of hydantoins such as the phenytoin drug in controlling seizures and the established safety drives their popularity in the market.
In the United States, the market is driven by the increasing prevalence of epilepsy and the availability of advanced treatment options. The strong presence of pharmaceutical companies and a well-established healthcare infrastructure also support market expansion. The market also benefits from the rising adoption of newer antiepileptic drugs and growing awareness about seizure treatment. Further, increased focus on the development of novel therapeutics for tonic-clonic seizures is expected to fuel the growth in this regional market.
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Global healthcare company GSK (GlaxoSmithKline plc) has a significant presence in the market and offers medications indicated for epilepsy, including drugs targeting tonic-clonic seizures. One of their key drugs is Lamotrigine (Lamictal) which helps to treat tonic-clonic seizures.
Headquartered in Tokyo, Japan, this Japanese pharmaceutical company has a strong portfolio in the neurology market including tonic-clonic seizure treatment. Its anti-epileptic drug (AED) Fycompa® is used for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures.
Biopharmaceutical company Catalyst Pharmaceutical Co. Ltd. is based in Coral Gables, Florida. The company specializes in the development and commercialization of innovative therapies for rare neurological diseases, including epilepsy and other seizure disorders.
Japanese pharmaceutical company Otsuka Pharmaceutical Co. Ltd. is one of the leading players in the market and enjoys a strong presence in the neurology sector. Its anti-epileptic medication E Keppra® (generic name: levetiracetam) is widely used for treating tonic-clonic and other types of seizures.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Prasco LLC, UCB Japan Co. Ltd., Pfizer Inc., Azurity Pharmaceuticals Inc., and GL Pharma.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Drug Generation |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share